Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $100M Series D (Feb 2026) at $1B unicorn valuation. 230K+ patients in 50 states. Digital health's first menopause-focused unicorn. Expanding to longevity and cardiology.
Midi Health became digital health's first menopause-focused unicorn in February 2026, raising $100 million in Series D financing at a $1 billion valuation. The company serves 230,000+ patients across all 50 states with clinician-led care for menopause, perimenopause, and midlife women's health — a market that has been systematically underserved by mainstream healthcare despite affecting 50 million American women.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.